List your tool

Head to head · 2026

Proscia vs Qureight

Pricing, free plans, ratings, features, pros and cons, side by side. Where one comes out ahead, we mark it.

Proscia

FDA-cleared digital pathology platform for primary diagnosis and biomarker research

4.3Not listed

Visit Proscia (opens Proscia in a new tab)

Qureight

Imaging biomarkers for lung and heart clinical trials, from a Cambridge deep-learning lab

4.1Not listed

Visit Qureight (opens Qureight in a new tab)

Who comes out ahead

Based only on the facts in our directory. The right pick still depends on the job you need done.

  • Lower starting price

    Not comparable

    Not comparable: Proscia does not list a price

  • Free plan

    Tie

    Neither has one

  • Higher rating

    Proscia

    4.3 against 4.1

  • Same job?

    Yes

    Both are Healthcare AI tools

Side by side

Compared onProsciaQureight
Our rating4.3Better4.1
Starts atNot listedNot listed
Free planNoNo
CategoryHealthcare AIHealthcare AI
PlansSee pricingSee pricing
Key features
  • FDA-cleared for primary clinical diagnosis in AP-Dx
  • Concentriq AP, AP-Dx and LS configurations
  • Biomarker research and clinical trial workflows
  • Cloud deployment
  • Predetermined Change Control Plan for regulatory compliance
  • Deep-learning lung imaging biomarkers Lung8, Air8 and Fibr8
  • Glass8 and Vascul8 for vascular and parenchymal measures
  • Central reads and endpoint discovery for trials
  • Imaging data curation and quality control
  • Built for pulmonary fibrosis, hypertension and bronchiectasis trials
Pros
  • FDA clearance for primary diagnosis, not just research viewing
  • Deployed across 4,000 hospitals and 16 of the top 20 pharma companies
  • Rated highest in KLAS 2026 in both the US and Europe
  • Consistent measurement reduces the variability that costs trial power
  • Named biomarkers rather than a generic imaging claim
  • Focused deeply on respiratory and cardiac disease
Cons
  • No published pricing
  • Requires compatible scanning hardware
  • Adoption is a laboratory-wide programme, not a purchase
  • No published pricing; sold to trial sponsors
  • Biomarkers need regulatory acceptance per context of use
  • Narrow therapeutic focus by design
CompanyProscia Inc.Qureight Ltd

Prices come from each vendor's pricing page, last checked 20260814. Check the vendor before you buy.

FAQ

Questions people ask

Is Proscia better than Qureight?

In our reviews Proscia scores 4.3 and Qureight scores 4.1. The better pick depends on the job. Proscia: FDA-cleared digital pathology platform for primary diagnosis and biomarker research. Qureight: Imaging biomarkers for lung and heart clinical trials, from a Cambridge deep-learning lab.

Which is cheaper, Proscia or Qureight?

Proscia: see pricing. Qureight: see pricing.

Do Proscia and Qureight have free plans?

Neither lists a free plan.

More comparisons

Proscia compared with

All Proscia alternatives

Qureight compared with

All Qureight alternatives